Recommendations to standardize preanalytical confounding factors in Alzheimers and Parkinsons disease cerebrospinal fluid biomarkers: An update

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 419-430

  Del Campo, Marta ^a   Mollenhauer, Brit ^b   Bertolotto, Antonio ^c   Engelborghs, Sebastiaan ^d   Hampel, Harald ^e   Simonsen, Anja Hviid ^f   Kapaki, Elisabeth ^g   Kruse, Niels ^b   Le Bastard, Nathalie ^d   Lehmann, Sylvain ^h   Molinuevo, Jose L ⁱ   Parnetti, Lucilla ^j   Perret Liaudet, Armand ^k   Sáez Valero, Javier ^l   Saka, Esen ^m   Urbani, Andrea ⁿ   Vanmechelen, Eugeen ^o   Verbeek, Marcel ^p   Visser, Pieter Jelle ^q   Teunissen, Charlotte ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Neurologia 2 CRESM (Centro Riferimento Regionale Sclerosi Multipla) Azienda Ospedaliera   (Italy)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e GOETHE UNIVERSITY   (Germany)

^f Mental Health Services CPH   (Denmark)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h UNIV MONTPELLIER   (France)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY OF PERUGIA   (Italy)

^k UNIVERSITÉ LYON 1   (France)

^l CSIC   (Spain)

^m HACETTEPE UNIVERSITY   (Turkey)

ⁿ IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^o ADX NEUROSCIENCES   (Belgium)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Alzheimers disease; biomarkers; CSF; early diagnosis; guidelines; Parkinsons disease; preanalytical factors; recommendations; standard operating procedures

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; DNA; POLYPROPYLENE; RNA; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD SAMPLING; CENTRIFUGATION; CEREBROSPINAL FLUID ANALYSIS; CIRCADIAN RHYTHM; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; CONTAMINATION; DIET RESTRICTION; DNA DETERMINATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE THAWING; FREEZING TEMPERATURE; HUMAN; INCUBATION TEMPERATURE; LENGTH OF STORAGE; LUMBAR PUNCTURE; NEEDLE; PARKINSON DISEASE; PRACTICE GUIDELINE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEOMICS; REVIEW; RNA ANALYSIS; ROTATION; STANDARDIZATION; STORAGE; TEMPERATURE; TUBE;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHASE TRANSITION; SPECIMEN HANDLING; TAU PROTEINS; TEMPERATURE;

EID: 84865477339     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.46     Document Type: Review

References (64)

1. Ho L, Fivecoat H, Wang J, Pasinetti GM. Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp. Gerontol. 45, 15-22 (2010).
2. Fortea J, Sala-Llonch R, Bartrés-Faz D et al. Cognitively preserved subjects with transitional cerebrospinal fluid b-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol. Psychiatry 70, 183-190 (2011).
3. Rami L, Sala-Llonch R, Solé-Padullés C et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. J. Alzheimers Dis. 30, 1-10 (2012).
4. Jack CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet 9, 1-20 (2010).
5. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455 (1973).
6. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci. 184, 101-122 (2001). (Pubitemid 32178265)
7. Teunissen C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging 23, 485-508 (2002). (Pubitemid 34495461)
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144 (2010).
9. Mulder C, Verwey NA, van der Flier WM et al. Amyloid-beta (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 56, 248-253 (2010).
10. Jack CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257-262 (2011).
11. Ibáñez P, Bonnet A-M, Débarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171 (2004). (Pubitemid 39296605)
12. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240 (2011).
13. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010).
14. Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid tau/a-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 1428-1435 (2011).
15. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. doi:10.1097/WAD.0b013e31823899cc (2011) (Epub ahead of print).
16. Mattsson N, Andreasson U, Persson S et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7, 386-395 e6 (2011).
17. Sunderland T, Linker G, Mirza N et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103 (2003). (Pubitemid 37430211)
18. Mollenhauer B, El-Agnaf O, Marcus K, Trenkwalder C, Schlossmacher M. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 4, 683-699 (2010).
19. Verwey NA, van der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46, 235-240 (2009).
20. Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409, 1-4 (2006). (Pubitemid 44740057)
21. Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int. J. Alzheimers. Dis. 2010, 1-5 (2010).
22. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic 429 www.futuremedicine. com guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292 (2011).
23. Bjerke M, Portelius E, Minthon L et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int. J. Alzheimers. Dis. 2010, 1-11 (2010).
24. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid ß ((1-42)), tau, and phosphorylated tau in Alzheimer's disease: report of an international workshop. Int. J. Alzheimers. Dis. 2010, pii: 635053 (2010).
25. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin. Chem. Lab. Med. 44, 750-759 (2006). (Pubitemid 43832871)
26. Perret-Liaudet A, Pelpel M, Tholance Y et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J. Alzheimers Dis. 30, 1-8 (2012).
27. Schoonenboom NSM, Mulder C, Vanderstichele H et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem. 51, 189-195 (2005). (Pubitemid 40024030)
28. Vanderstichele H, Bibl M, Engelborghs S et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 8, 65-73 (2012).
29. Teunissen C, Petzold A, Bennett J et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914-1922 (2009).
30. Murillo-Rodriguez E, Désarnaud F, Prospéro-García O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci. 79, 30-37 (2006).
31. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68, 666-669 (2007). (Pubitemid 46667813)
32. Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid ab and tau level fluctuation in an older clinical cohort. Arch. Neurol. 69, 246-250 (2012).
33. Slats D, Claassen JAHR, Spies PE et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol. Aging 33, 831.e1-9 (2012).
34. Frasier M, Chowdhury S, Sherer T et al. The Parkinson's progression markers initiative: a prospective biomarker study. Mov. Disord. 95(4), 629-635 (2010).
35. Spies PE, Slats D, Rikkert MGO, Tseng J, Claassen JA, Verbeek MM. CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid b in humans. Neurosci. Lett. 504, 336-338 (2011).
36. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clinica Chimica Acta 310, 173-186 (2001). (Pubitemid 32728347)
37. Simonsen AH, Bech S, Laursen I et al. Proteomic investigations of the ventriculolumbar gradient in human CSF. J. Neurosci. Methods 191, 244-248 (2010).
38. Blennow K, Fredman P, Wallin A, Gottfries CG, Långström G, Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur. Neurol. 33, 126-128 (1993). (Pubitemid 23100536)
39. Blennow K, Wallin A, Gottfries CG, Månsson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J. Neural. Transm. Park. Dis. Dement. Sect. 5, 5-15 (1993). (Pubitemid 23038785)
40. Mollenhauer B, Trautmann E, Otte B et al. α-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural. Transm. doi:10.1007/s00702-012-0784-0780 (2012) (Epub ahead of print).
41. Kuntz KM, Kokmen E, Stevens JC, Miller P, Offord KP, Ho MM. Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology 42, 1884-1887 (1992).
42. Netto CBO, Conte S, Leite MC et al. Serum S100B protein is increased in fasting rats. Arch. Med. Res. 37, 683-686 (2006). (Pubitemid 43782910)
43. Lehmann S, Roche S, Allory Y et al. [Preanalytical guidelines for clinical proteomics investigation of biological fluids]. Ann. Biol. Clin. (Paris) 67, 629-639 (2009).
44. Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D et al. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement. 6, 25-38 (2010).
45. Rye PD, Booij BB, Grave G et al. A novel blood test for the early detection of Alzheimer's disease. J. Alzheimers Dis. 23, 121-129 (2011).
46. Lewczuk P, Beck G, Esselmann H et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin. Chem. 52, 332-334 (2006). (Pubitemid 43185505)
47. Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF. Nonspecific binding of Ab42 to polypropylene tubes and the effect of Tween-20. Clin. Chim. Acta 411, 1833 (2010).
48. Petzold A, Sharpe LT, Keir G. Spectrophotometry for cerebrospinal fluid pigment analysis. Neurocrit. Care 4, 153-162 (2006). (Pubitemid 43793349)
49. You J-S, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5, 290-296 (2005). (Pubitemid 40189659)
50. Berven FS, Kroksveen AC, Berle M et al. Preanalytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin. Appl. 1, 699-711 (2007).
51. Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin. Appl. 1, 1385-1392 (2007).
52. West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Schou C, Heegaard NHH. Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem. 77, 5114-5123 (2005). (Pubitemid 41140826)
53. Rosenling T, Slim CL, Christin C et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J. Proteome Res. 8, 5511-5522 (2009).
54. Kaiser E, Schönknecht P, Thomann P, Hunt A, Schröder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci. Lett. 417, 193-195 (2007). (Pubitemid 46551360)
55. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J. Alzheimers Dis. 25, 739-745 (2011).
56. Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B. Development of electrochemiluminescencebased singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Methods (San Diego, Calif) 56(4), 514-518 (2012).
57. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm. Dev. Technol. 12, 505-523 (2007). (Pubitemid 350041532)
58. Chaigneau C, Cabioch T, Beaumont K, Betsou F. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin. Chem. Lab. Med. 45, 1390-1395 (2007). (Pubitemid 47557062)
59. Nishino S, Ripley B, Overeem S et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 50, 381-388 (2001). (Pubitemid 32848741)
60. Botella-López A, Burgaya F, Gavín R et al. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 5573-5578 (2006).
61. Sjögren M, Vanderstichele H, Agren H et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 47, 1776-1781 (2001). (Pubitemid 32881189)
62. Bibl M, Esselmann H, Otto M et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 25, 2912-2918 (2004). (Pubitemid 39294839)
63. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez J-C. Truncated cystatin C in cerebrospiral fluid: technical [corrected] artefact or biological process? Proteomics 5, 3060-3065 (2005). (Pubitemid 41176472)
64. Schipke CG, Jessen F, Teipel S et al. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. J. Alzheimers Dis. 26, 255-262 (2011).